

**IN THE UNITED STATES DISTRICT COURT  
FOR THE WESTERN DISTRICT OF PENNSYLVANIA**

BAUSCH HEALTH IRELAND LIMITED,	)	
and SALIX PHARMACEUTICALS, INC.,	)	
	)	
Plaintiffs,	)	
	)	
v.	)	
	)	
MYLAN LABORATORIES LTD.,	)	Civil Action No. 21-573
AGILA SPECIALTIES INC., MYLAN	)	
API US LLC, MYLAN INC.,	)	
VIATRIS INC., and MYLAN	)	
PHARMACEUTICALS INC. -	)	
A VIATRIS COMPANY,	)	
	)	
Defendants.	)	

**ORDER OF COURT**

AND NOW, this 6<sup>th</sup> day of April, 2022, upon consideration of Defendants’ Unopposed Motion to Stay (Docket No. 68) filed by Defendants Mylan Laboratories Ltd., Agila Specialties Inc., Mylan API US LLC, MYLAN Inc., Viatris Inc., and Mylan Pharmaceuticals Inc, and based on the fact that Plaintiffs’ first-filed, substantively similar action is now proceeding in the Northern District of West Virginia, IT IS ORDERED that said motion is GRANTED. This matter shall be stayed and administratively closed until the disposition of *Bausch Health Ireland Ltd., et al. v. Mylan Labs. Ltd., et al.*, No. 1:22-cv-00020-TSK, in the Northern District of West Virginia, including any potential appeal. The parties shall notify this Court within 30 days of the disposition of the above mentioned case.

IT IS FURTHER ORDERED that Defendant’s Motion to Dismiss (Docket No. 25) and Plaintiffs’ Cross-Motion for Venue/Jurisdictional Discovery (Docket No. 45) are DENIED without prejudice to refile, and Plaintiffs’ Motion to Stay the Second-Filed Case in the Western

District of Pennsylvania (Docket No. 47) is DENIED AS MOOT.

s/ W. Scott Hardy  
W. Scott Hardy  
United States District Judge

cc/ecf: All counsel of record